SCHEMBL304697

SCHEMBL304697

O=C(O)N1CCC(n2nnc3c(Cl)ncnc32)CC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 1/20 0.39
JAK2 O60674 3/20 0.38
JAK3 P52333 3/20 0.38
JAK1 P23458 1/20 0.38
ALDH1A1 P00352 4/20 0.34
USP2 O75604 1/20 0.34
LMNA P02545 1/20 0.34
TSHR P16473 1/20 0.34
HCAR3 P49019 3/20 0.33
BTK Q06187 2/20 0.33
FGFR1 P11362 2/20 0.33
FGFR4 P22455 2/20 0.33
EGFR P00533 1/20 0.33
MEN1 O00255 1/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
KMT2A Q03164 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
FGFR2 P21802 1/20 0.32
FGFR3 P22607 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24687442 0.83 ADORA2A (0.36) GPR119JAK2ALDH1A1LMNAHCAR3
SCHEMBL9943531 0.83 GPR119 (0.56) GPR119EGFRPOLB
SCHEMBL9943529 0.81 GPR119 (0.34) GPR119
SCHEMBL21138790 0.81 ADORA2A (0.39) HCAR3EGFR
SCHEMBL11622927 0.79 ADORA2A (0.40) ALDH1A1LMNAHCAR3EGFRSMN1; SMN2
SCHEMBL304484 0.79 ALDH1A1 (0.41) ALDH1A1USP2LMNATSHRHCAR3
SCHEMBL305622 0.78 ADORA2A (0.47) FGFR1FGFR4SMN1; SMN2
SCHEMBL21138787 0.77 TP53 (0.43) GPR119LMNAEGFR
SCHEMBL21138788 0.75 AHCY (0.32) GPR119EGFR
SCHEMBL305394 0.73 GPR119 (0.65) GPR119ALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8476283-B2 [6,5]—bicyclic GPR119 G protein-coupled receptor agonists BRISTOL-MYERS SQUIBB COMPANY (US) 2013-07-02 US disclosed
US-20120077826-A1 [6,5] - BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS BRISTOL-MYERS SQUIBB COMPANY 2012-03-29 US disclosed
US-8093257-B2 [6,5]-bicyclic GPR119 G protein-coupled receptor agonists BRISTOL-MYERS SQUIBB COMPANY (US) 2012-01-10 US disclosed
EP-2152707-A1 [6,5]-BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS Bristol-Myers Squibb Company (US) 2010-02-17 EP disclosed
US-20090018055-A1 [6,5]-BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS BRISTOL-MYERS SQUIBB COMPANY 2009-01-15 US disclosed
WO-2008137436-A1 [6,5]-BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS BRISTOL-MYERS SQUIBB COMPANY (US) 2008-11-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090018055-A1 [6,5]-BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS GPR119, GPR139, GPR4 GPR119 1/4885JAK2 2739/4885JAK3 4216/4885
US-20120077826-A1 [6,5] - BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS GPR119, GPR139, GPR4 GPR119 1/4885JAK2 2739/4885JAK3 4216/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.